Clinical care of a child with hemophilia A and inhibitors

Surbhi Saini, Amy L. Dunn

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies to factor VIII. Patient-related and treatment-related factors have been implicated in inhibitor development. Inhibitor development is associated with significant morbidity, and decreased quality of life, and is currently the most challenging complication in the management of patients with hemophilia. Hemostatic bypassing agents are used to control bleeding episodes in patients with inhibitors, while the cornerstone of management is inhibitor eradication by immune tolerance. Newer nonfactor products are rapidly changing the landscape of inhibitor management.

Original languageEnglish
Title of host publicationPediatric Bleeding Disorders
Subtitle of host publicationA Clinical Casebook
PublisherSpringer International Publishing
Number of pages11
ISBN (Electronic)9783030316617
ISBN (Print)9783030316600
StatePublished - Jan 1 2020


  • Bypassing agents
  • Hemophilia A
  • Immune tolerance therapy
  • Inhibitors


Dive into the research topics of 'Clinical care of a child with hemophilia A and inhibitors'. Together they form a unique fingerprint.

Cite this